The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

被引：2
|
作者：
Addeo, Raffaele [1 ]
Caraglia, Michele [2 ]
机构：
[1] S Giovanni di Dio Hosp, Oncol Unit, ASL Napoli 2, I-80027 Naples, Italy
[2] Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2011年 / 11卷 / 02期
关键词：
blood-brain barrier; brain metastasis; breast cancer; chemotherapy; lapatinib; sunitinib; tyrosine kinase inhibitor; whole-brain radiotherapy; NERVOUS-SYSTEM METASTASES; PHASE-II TRIAL; TEMOZOLOMIDE; CARCINOMA; RADIOTHERAPY; CAPECITABINE; BEVACIZUMAB; COMBINATION; THERAPY; DISEASE;
D O I：
10.1586/ERA.10.190
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：139 / 142
页数：4
相关论文
共 50 条
  • [21] RON tyrosine kinase mutations in brain metastases from lung cancer
    Milan, Melissa
    Benvenuti, Silvia
    Balderacchi, Alice Maria
    Virzi, Anna Rita
    Gentile, Alessandra
    Senetta, Rebecca
    Cassoni, Paola
    Comoglio, Paolo Maria
    Stella, Giulia Maria
    ERJ OPEN RESEARCH, 2018, 4 (01)
  • [22] Tyrosine kinase inhibitors in breast cancer (Review)
    Iancu, George
    Serban, Dragos
    Badiu, Cristinel Dumitru
    Tanasescu, Ciprian
    Tudosie, Mihai Silviu
    Tudor, Corneliu
    Costea, Daniel Ovidiu
    Zgura, Anca
    Iancu, Raluca
    Vasile, Danut
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (02)
  • [23] Breast Cancer Brain Metastases: Challenges and Opportunities
    Peereboom, David M.
    JCO ONCOLOGY PRACTICE, 2024, 20 (10)
  • [24] Lapatinib as a therapeutic option in brain metastases from HER2+ breast cancer
    Markman, Maurie
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (01) : 35 - 36
  • [25] Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
    Nader-Marta, G.
    Martins-Branco, D.
    Agostinetto, E.
    Bruzzone, M.
    Ceppi, M.
    Danielli, L.
    Lambertini, M.
    Kotecki, N.
    Awada, A.
    de Azambuja, E.
    ESMO OPEN, 2022, 7 (03)
  • [26] Tyrosine-kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Spanheimer, P. M.
    Kulak, M. V.
    Carr, J. C.
    Woodfield, G. W.
    De Andrade, J. P.
    Sugg, S. L.
    Weigel, R. J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S11 - S11
  • [27] Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Spanheimer, Philip M.
    Lorenzen, Allison W.
    De Andrade, James P.
    Kulak, Mikhail V.
    Carr, Jennifer C.
    Woodfield, George W.
    Sugg, Sonia L.
    Weigel, Ronald J.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (13) : 4287 - 4294
  • [28] Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Philip M. Spanheimer
    Allison W. Lorenzen
    James P. De Andrade
    Mikhail V. Kulak
    Jennifer C. Carr
    George W. Woodfield
    Sonia L. Sugg
    Ronald J. Weigel
    Annals of Surgical Oncology, 2015, 22 : 4287 - 4294
  • [29] Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis
    Yu, Yushuai
    Huang, Kaiyan
    Lin, Yuxiang
    Zhang, Jie
    Song, Chuangui
    CANCER MEDICINE, 2023, 12 (14): : 15090 - 15100
  • [30] Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
    Ito Y.
    Tokudome N.
    Sugihara T.
    Takahashi S.
    Hatake K.
    Breast Cancer, 2007, 14 (2) : 156 - 162
12345